Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients
Autore:
Hefler, L; Tempfer, C; Heinze, G; Mayerhofer, K; Breitenecker, G; Leodolter, S; Reinthaller, A; Kainz, C;
Indirizzi:
Univ Vienna, Sch Med, Dept Obstet & Gynaecol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 tet & Gynaecol, A-1090 Vienna, Austria Univ Vienna, Sch Med, Dept Med Comp Sci, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Med Comp Sci, A-1090 Vienna, Austria Univ Vienna, Sch Med, Dept Gynaecopathol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 Gynaecopathol, A-1090 Vienna, Austria Baylor Coll Med, Dept Obstet & Gynaecol, Houston, TX 77030 USA Baylor CollMed Houston TX USA 77030 et & Gynaecol, Houston, TX 77030 USA
Titolo Testata:
BRITISH JOURNAL OF CANCER
fascicolo: 5, volume: 81, anno: 1999,
pagine: 855 - 859
SICI:
0007-0920(199911)81:5<855:MCPSLI>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-VIVO; CHEMOTACTIC PROTEIN-1; EXPRESSION; TUMOR; MCP-1; MACROPHAGES; CHEMOKINES; INFILTRATION; CELLS;
Keywords:
MCP-1; ovarian cancer; prognosis; differentiation marker;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Hefler, L Univ Vienna, Sch Med, Dept Obstet & Gynaecol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
L. Hefler et al., "Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients", BR J CANC, 81(5), 1999, pp. 855-859

Abstract

The chemokine monocyte chemoattractant protein (MCP)-1 is an important mediator of monocyte infiltration in various solid tumours of epithelial origin. The aim of the present study was to evaluate the role of MCP-1 in the natural history of ovarian cancer and to determine its Value as differentiation marker and prognostic marker regarding disease free and overall survival. This retrospective study comprises 86 patients with ovarian cancer, 48 with primary ovarian cancer and 38 with recurrent ovarian cancer, 67 patientswith benign ovarian cysts and 42 healthy women. Median serum levels in patients with primary ovarian cancer, recurrent ovarian cancer, benign ovariancysts and in healthy women were 535.6 (range 129.6-1200) pg ml(-1), 427.3 (range 193.4-1101) pg ml(-1), 371.2 (range 222-986.8) pg ml(-1) and 318.7 (range 241.3-681.4) pg ml(-1) respectively (Mann-Whitney CI-test, P < 0.001). Univariate logistic regression models revealed a significant influence ofMCP-1 serum levels on the odds of presenting with primary ovarian cancer Versus benign cysts and Versus healthy women respectively (univariate logistic regression, P < 0.001 and P < 0.001 respectively). In a multivariate logistic regression model considering MCP-1 and CA 125 serum levels simultaneously both MCP-1 and CA 125 revealed statistical significance on the odds ofpresenting with primary ovarian cancer versus benign cysts (multivariate logistic regression, P = 0.05 and P < 0.001 respectively). In ovarian cancerpatients, MCP-1 serum levels showed a statistically significant correlation with histological grade (Mann-Whitney U-test, P = 0.02) and age at the time of diagnosis (Mann-Whitney U-test, P = 0.03). Elevated MCP-1 serum levels prior to therapy were not associated with disease-free and overall survival (log-rank test, P = 0.2 and P = 0.7 respectively). In summary these dataindicate that MCP-1 might play a functional role in the natural history ofovarian cancer and might serve as differentiation marker between benign ovarian cysts and ovarian cancer, providing additional information to the established tumour marker CA 125.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/07/20 alle ore 13:42:06